Clinical challenges in a patient with dabigatran-induced fatal hemorrhage

American Journal Geriatric Pharmacotherapy

Volumn 10, Issue 2, 2012, Pages 160-163

  Cano, Ennie L ^a   Miyares, Marta A ^a  

^a JACKSON MEMORIAL HOSPITAL   (United States)

Author keywords

bleeding; dabigatran; direct thrombin inhibitor; prothrombin complex concentrate; recombinant factor VIIa

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BICARBONATE; BLOOD CLOTTING FACTOR 9 COMPLEX; CARBON DIOXIDE; CREATININE; DABIGATRAN; HEMOGLOBIN; OXYGENASE; VITAMIN K GROUP;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTERIAL GAS; ARTICLE; ARTIFICIAL VENTILATION; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CARBON DIOXIDE TENSION; BLOOD CLOTTING DISORDER; BLOOD CULTURE; BLOOD SAMPLING; BODY TEMPERATURE; BREATHING RATE; CASE REPORT; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DEATH; DIARRHEA; DRUG INDUCED DISEASE; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEMATOCRIT; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HEMOSTASIS; HUMAN; HYPERTENSION; HYPOTENSION; INTENSIVE CARE UNIT; INTERNATIONAL NORMALIZED RATIO; LIVER FUNCTION TEST; LUNG ADENOCARCINOMA; LUNG HEMORRHAGE; LUNG RESECTION; MEAN ARTERIAL PRESSURE; NAUSEA; OSTEOPOROSIS; OXYGEN SATURATION; PARTIAL THROMBOPLASTIN TIME; PH; PRIORITY JOURNAL; PROTHROMBIN TIME; PULSE RATE; RESPIRATORY FAILURE; RETROPERITONEAL HEMORRHAGE; THROMBOCYTE COUNT; VOMITING;

AGED; ANTICOAGULANTS; BENZIMIDAZOLES; BETA-ALANINE; FATAL OUTCOME; FEMALE; HEMORRHAGE; HUMANS; HYPOTENSION; RESPIRATORY INSUFFICIENCY; SEVERITY OF ILLNESS INDEX;

EID: 84859549864     PISSN: 15435946     EISSN: 18767761     Source Type: Journal    
DOI: 10.1016/j.amjopharm.2012.02.004     Document Type: Article

References (17)

1. Legrand M, Mateo J, Aribaud A, et al. The use of dabigatran in elderly patients. Arch Intern Med. 2011;171: 1285-88.
2. Samama MM, Guinet C. Laboratory assessment of new anticoagulants. Clin Chem Lab Med. 2011;49:761-772.
3. Van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate, a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103:1116-1127.
4. Elg M, Carlsson S, Gustafsson D. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor. Thromb Res. 2001;101:145-157. (Pubitemid 32176020)
5. Elg M, Carlsson S, Gustafsson D. Effect of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthetized rats and rabbits. Thromb Res. 2001;101:159-170. (Pubitemid 32176021)
6. Gruber A, Carlsson S, Kotze HF, et al. Hemostatic effect of activated factor VII without promotion of thrombus growth in melagatran-anticoagulated primates. Thromb Res. 2007;119:121-127. (Pubitemid 44794355)
7. Blombäck M, He S, Bark N, et al. Effects on fibrin network porosity of anticoagulants with different modes of action and reversal by activated coagulation factor concentrate. Br J Haematol. 2011;152:758-765.
8. Wolzt M, Levi M, Sarich TC, et al. Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers. Thromb Haemost. 2004;91:1090-1096. (Pubitemid 38821264)
9. Sørensen B, Ingerslev J. A direct thrombin inhibitor studied by dynamic whole blood clot formation: haemostatic response to ex-vivo addition of recombinant factor VIIa or activated prothrombin complex concentrate. Thromb Haemost. 2006;96:446-453. (Pubitemid 44560678)
10. Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate. Circulation. 2011;124:1573- 1579.
11. Product information. Dabigatran (Pradaxa). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; August 2011.
12. Lindahl TL, Baghaei F, Blixter IF, et al. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost. 2011;105: 371-378.
13. Baruch L, Sherman O. Potential inaccuracy of point-of-care INR in dabigatran-treated patients. Ann Pharmacother. 2011;45:e40.
14. DeRemer CE, Gujral JS, Thornton JW, et al. Dabigatran falsely elevates point of care international normalized ratio results. Am J Med. 2011;124:e5-e6.
15. Stangier J, Rathgen K, Stähle H, et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallelgroup, single-centre study. Clin Pharmacokinet. 2010; 49:259-268.
16. Pradaxa (dabigatran etexilate): Advisory Committee briefing document. Ridgefield, Conn: Boehringer Ingelheim Pharmaceuticals, Inc.; August 27, 2010. http://www.fda.gov/ downloads/advisorycommittees/committeesmeetingmate rials/drugs/cardiovascularandrenaldrugsadvisory committe/ucm226009.pdf. Accessed November 3, 2011.
17. US Food and Drug Administration. Dabigatran etexilate. Advisory Committee briefing document. http://www.fda. gov/downloads/advisorycommittees/ committeesmeeting materials/drugs/cardiovascularandrenaldrugsadvisory committee/ucm226009.pdf 30. Accessed December 20, 2011.